P4‐047: Nicotinamide Riboside Promotes Cognitive Function and Synaptic Plasticity in an Alzheimer's Mouse Model Through Up Regulation of PGC‐1a‐mediated BACE1 Degradation

Bing Gong,Pan Yong,Lindsay Knable,Prashant Vempati,Lap Ho,Jun Wang,Giulio Pasinetti

DOI: https://doi.org/10.1016/j.jalz.2012.05.1748

2012-01-01

Abstract:Nicotinamide adenine dinucleotide (NAD)+ has been identified as a key regulator of the lifespan extending effects of calorie restriction (CR), and the activation of NAD + expression has been linked with a decrease in amyloid toxicity in Alzheimer's disease (AD). Nicotinamide Riboside (NR) is a NAD + precursor, which is a coenzyme involved in redox activities in the mitochondrial electron transport chain and promotes peroxisome proliferator-activated receptor (PPAR)-γ co-activator 1 (PGC)-1α expression in the brain. Increasing evidence has shown that PGC-1α is a crucial regulator of beta-Amyloid (Aβ) clearance by affecting BACE1 degradation. In this study we tested the hypothesis that NR treatment in an AD mouse model could attenuate Aβ toxicity through the activation of PGC-1α-mediated BACE1 degradation. Using the Tg2576 AD mouse model, we explored the impacts of dietary NR treatment on cognitive function, PGC-1± expression, BACE1 degradation, and the reduction of Aβ production, as assessed by in vivo behavioral analyses, biochemistry assays and shRNA gene silencing. We further tested the effects of NR treatment on synaptic plasticity in hippocampal slices. We found 1) dietary treatment of Tg2576 mice with 250 mg/kg/day of NR for three months significantly attenuates cognitive deterioration in Tg2576 mice and coincides with an increase in the steady-state levels of NAD + in the cerebral cortex; 2) NR treatment promotes PGC-1α expression in the brain coinciding with enhanced degradation of BACE1 and the reduction of Aβ production in Tg2576 mice. Further in vitro studies confirmed that BACE1 protein content is decreased by NR treatment in primary neuronal cultures derived from Tg2576 embryos, in which BACE1 degradation was prevented by PGC-1α shRNA gene silencing; 3) In mechanistic studies, we found that both NR treatment and PGC-α Nicotinamide riboside promotes 1α overexpression enhance BACE1 ubiquitination and proteasomal degradation; 4) We further applied NR to hippocampal slices (10μM) for 4 hrs and the deficits in LTP recorded in the CA1 region of Tg2576 mice was greatly abolished. Results from our studies suggest that dietary treatment with NR may benefit AD cognitive function and synaptic plasticity, in part by promoting PGC-1α mediated BACE1 ubiquitination and degradation, thus preventing Aβ production in the brain.